Zacks Investment Research upgraded shares of OraSure Technologies (NASDAQ:OSUR) from a sell rating to a hold rating in a research note published on Saturday.
According to Zacks, “OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, in vitro diagnostic tests, and other medical devices. “
A number of other research analysts have also commented on the stock. BidaskClub upgraded shares of OraSure Technologies from a hold rating to a buy rating in a research note on Thursday, December 21st. ValuEngine lowered shares of OraSure Technologies from a buy rating to a hold rating in a research note on Thursday, November 2nd. Jefferies Group lowered shares of OraSure Technologies from a buy rating to a hold rating in a research note on Thursday, November 2nd. Finally, Canaccord Genuity reiterated a buy rating and issued a $22.00 price target on shares of OraSure Technologies in a research note on Tuesday, September 19th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $19.65.
OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.09. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The business had revenue of $42.30 million for the quarter, compared to analyst estimates of $40.87 million. During the same quarter in the prior year, the business earned $0.11 EPS. OraSure Technologies’s quarterly revenue was up 31.0% on a year-over-year basis. equities research analysts forecast that OraSure Technologies will post 0.42 EPS for the current year.
In related news, Director Mara G. Aspinall purchased 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 7th. The shares were acquired at an average price of $14.23 per share, for a total transaction of $71,150.00. Following the purchase, the director now owns 5,000 shares in the company, valued at $71,150. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 6.40% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Profund Advisors LLC boosted its holdings in OraSure Technologies by 2.8% in the 2nd quarter. Profund Advisors LLC now owns 10,903 shares of the medical instruments supplier’s stock valued at $188,000 after purchasing an additional 293 shares during the period. Timber Hill LLC boosted its holdings in OraSure Technologies by 3.2% in the 2nd quarter. Timber Hill LLC now owns 11,597 shares of the medical instruments supplier’s stock valued at $200,000 after purchasing an additional 363 shares during the period. Arizona State Retirement System boosted its holdings in OraSure Technologies by 3.4% in the 2nd quarter. Arizona State Retirement System now owns 30,100 shares of the medical instruments supplier’s stock valued at $520,000 after purchasing an additional 1,000 shares during the period. Victory Capital Management Inc. boosted its holdings in OraSure Technologies by 17.6% in the 2nd quarter. Victory Capital Management Inc. now owns 9,070 shares of the medical instruments supplier’s stock valued at $157,000 after purchasing an additional 1,360 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in OraSure Technologies by 3.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 44,672 shares of the medical instruments supplier’s stock valued at $772,000 after purchasing an additional 1,573 shares during the period. 94.43% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This news story was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://sportsperspectives.com/2018/01/03/zacks-investment-research-upgrades-orasure-technologies-osur-to-hold.html.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.